Show summary Hide summary
President Trump just signed a historic executive order that could revolutionize mental health treatment in America. The order directs the FDA to dramatically expedite review of psychedelic drugs like psilocybin and MDMA, making life-changing treatments available to veterans and patients suffering from depression and PTSD faster than ever before.
🔥 Quick Facts
- Signed Saturday: April 18, 2026, Trump issued the order in the Oval Office with HHS Secretary Robert F. Kennedy Jr.
- FDA Acceleration: Three national priority vouchers issued for psychedelics, potentially cutting approval from 1+ years to weeks.
- Federal Funding: $50 million made available to support state-level ibogaine research and Right to Try access.
- Substances Targeted: Psilocybin, MDMA, ibogaine, and LSD designated as breakthrough therapies for PTSD, depression, and trauma.
Trump Makes Stunning Move to Transform Mental Health Care
On Saturday, President Trump signed an executive order that could fundamentally reshape how Americans access psychedelic-assisted therapy. The move reflects a dramatic shift in federal drug policy, ending decades of restrictions on substances many researchers now see as revolutionary treatments.
Trump stated the order will “dramatically accelerate access to new medical research and treatments based on psychedelic drugs.” The president emphasized that experimental treatments have shown “life-changing potential” for veterans struggling with suicide rates that claim dozens daily.
Executive order directs FDA to expedite psychedelic drug review
Trump executive orders FDA to expedite psychedelics review, cites veterans’ mental health
FDA to Issue Guidance and Triple Review Speed
The executive order directs the Food and Drug Administration to issue new guidance for researchers conducting clinical trials on psychedelics. Most dramatically, FDA Commissioner Marty Makary announced that under the new program, drugs can receive approval “in weeks, not a year or a year plus” if aligned with national priorities.
Three national priority vouchers will be issued specifically for psychedelics. These fast-track vouchers target psilocybin-assisted therapy and MDMA-assisted treatment, both designated as “breakthrough therapies.” Makary also announced the first ibogaine investigational new drug clearance, paving the way for first-ever U.S. human trials.
Breaking Down What Changes Under the Order
| Element | What Changed |
| Review Timeline | Weeks instead of 1-2 years for approved substances |
| Bureaucratic Hurdles | Removed unnecessary FDA obstacles for researchers |
| VA Data Sharing | FDA coordinates with Veterans Affairs on trials |
| Rescheduling Pathway | DEA/DOJ coordinated reviews after Phase 3 trials |
| Right to Try Access | Ibogaine available to critically ill patients immediately |
“We’re taking this decisive step to confront one of the most urgent public health challenges facing our nation, the mental health crisis. This executive order will remove legal impediments that block American researchers, scientists, physicians and clinicians from properly studying these medicines.”
— Robert F. Kennedy Jr., HHS Secretary
Why Veterans and Mental Health Advocates Are Celebrating
Psychedelic therapy has emerged as potentially transformative for PTSD, traumatic brain injuries, and severe depression. HHS Secretary Kennedy specifically highlighted military veterans, a population facing unprecedented mental health crises. Studies suggest psilocybin-assisted therapy produces therapeutic breakthroughs in 50 to 70% of PTSD patients in clinical trials.
The order allocates $50 million to state-level ibogaine research and opens Right to Try pathways for the substance. This means terminally ill or severely suffering patients can access experimental treatments without waiting for full FDA approval. Veterans Affairs Secretary Doug Collins has already signaled interest in providing vouchers to cover psychedelic-assisted therapy outside VA facilities.
What Makes This Executive Order Historic for Mental Health?
For decades, federal drug scheduling classified psychedelics as Schedule I substances, meaning zero official medical use. This classification made research nearly impossible, despite international evidence of therapeutic benefits.
Trump’s action bypasses traditional legislative processes and directly empowers FDA leadership to accelerate approvals. If psilocybin or MDMA therapy completes Phase 3 trials successfully, approval could happen in a matter of weeks, not years. This represents the most aggressive federal push for psychedelic therapy access since the substances were first restricted in the 1960s.
